LBH589 (Panobinostat) treatment of a gastric cancer cell line
收藏官方服务：
资源简介：
LBH589 (Panobinostat) treatment of a gastric cancer cell line
应用场景：
创建时间：
2012-04-14
相关数据集
A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1. Plasmodium falciparum
Although artemisinin combination therapies have succeeded in reducing the global burden of malaria, multidrug resistance of the deadliest malaria parasite, Plasmodium falciparum, is emerging worldwide
NIAID Data Ecosystem80
Histone Deacetylase Inhibitors Global Market Report 2024
Global histone deacetylase inhibitors market size is expected to reach $1.64 billion by 2028 at a rate of 8.0%, segmented as by classification, class i histone deacetylases (hdacs), class ii histone d
www.thebusinessresearchcompany.com60
X-linked myotubular myopathy is associated with epigenetic alterations and is ameliorated by HDAC inhibition. X-linked myotubular myopathy is associated with epigenetic alterations and is ameliorated by HDAC inhibition
X-linked myotubular myopathy (XLMTM) is a fatal neuromuscular disorder caused by loss of function mutations in MTM1 . At present, there are no directed therapies for XLMTM, and incomplete understandin
NIAID Data Ecosystem50
A novel histone deacetylases inhibitor exerts promising anti-breast cancer activity via triggering AIFM1-dependent programmed necrosis. A novel histone deacetylases inhibitor exerts promising anti-breast cancer activity via triggering AIFM1-dependent programmed necrosis
Breast cancer is one of the most lethal cancers in women, and its resistance to chemotherapy remains a challenging problem. Histone deacetylases inhibitors (HDACIs) are a promising therapeutic tool fo
NIAID Data Ecosystem60
HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates
The zinc-containing histone deacetylase enzyme HDAC7 is emerging as an important regulator of immunometabolism and cancer. Here, we exploit a cavity in HDAC7, filled by Tyr303 in HDAC1, to derive new
NIAID Data Ecosystem60
